Characterization of Gp41 Polymorphisms in the Fusion Peptide Domain and T-20 (Enfuvirtide) Resistance-Associated Regions in Korean HIV-1 Isolates
- Authors
- Jang, Dai-Ho; Yoon, Cheol-Hee; Choi, Byeong-Sun; Chung, Yoon-Seok; Kim, Hye-Young; Chi, Sung-Gil; Kim, Sung Soon
- Issue Date
- 3월-2014
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Keywords
- Fusion Inhibitor; Fusion Peptide; Gp41 Polymorphism; HIV-1 Envelope Glycoprotein; T-20 Resistance Mutation
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE, v.29, no.3, pp.456 - 459
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- Volume
- 29
- Number
- 3
- Start Page
- 456
- End Page
- 459
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/99249
- DOI
- 10.3346/jkms.2014.29.3.456
- ISSN
- 1011-8934
- Abstract
- HIV-1 gp41 is an envelope protein that plays an essential role in virus entry. The mutation of gp41 affects HIV-1 entry and susceptibility to the fusion inhibitor T-20. Therefore, we analyzed the natural polymorphism of gp41 of 163 HIV-1 isolates from T-20-naive Koreans infected with HIV-1. This study of gp41 polymorphisms showed that insertions in the fourth threonine (74.8%) and L7M substitutions (85.3%) were more frequent in the fusion peptide motif in Korean HIV-1 isolates compared with those from other countries. Minor T-20 resistance mutations such as L45M (1.2%), N126K (1.2%), and E137K (6.7%) were detected, but the critical T-20 resistance mutations were not detected in the gp41 HR1 and HR2 regions. In addition, the N42S mutation (12.9%) associated with T-20 hypersusceptibility was detected at a high frequency. These results may serve as useful data for studies considering T-20 for use in the development of a more effective anti-retroviral treatment in Korea.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Life Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.